Aleix Prat

Sobre mi

Publicacions destacades

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;

  (...)

  Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2022.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Autors:

  Prat, A; Chaudhury, A; Solovieff, N; Paré, L; Martinez, D;

  (...)

  Brasó-Maristany, F; Lteif, A; Taran, T; Babbar, N; Su, F.

  Veure llistat complet d'autors

  Referència: Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• Immune-related adverse events of checkpoint inhibitors

  Autors:

  Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N;

  Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME .

  Referència: Nature Reviews Disease Primers 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autors:

  Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

  (...)

  Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

  Veure llistat complet d'autors

  Referència: Cancer Treatment Reviews 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Autors:

  Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

  (...)

  Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

  Veure llistat complet d'autors

  Referència: Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Autors:

  Prat A; Saura C; Pascual T; Hernando C; Muñoz M;

  (...)

  López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Autors:

  Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A;

  (...)

  Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.

  Veure llistat complet d'autors

  Referència: Journal Of The National Cancer Institute 2020.

• A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

  Autors:

  Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S;

  (...)

  Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R .

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2019.

• Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.

  Autors:

  Pare, L; Pascual, T; Segui, E; Teixido, C; Gonzalez-Cao, M;

  (...)

  Juan, M; Llovet, J M; Reguart, N; Arance, A; Prat, A.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2018.

Projectes destacats

• RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

  Investigador/a principal: Aleix Prat Aparicio, Antoni Hurtado Rodríguez

  Finançador: European Commission

  Codi: H2020-SC1-BHC-02-2019 / 847912-2

  Durada: 01/01/2020 - 31/12/2024

• Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Asociación Española Contra el Cáncer

  Codi: GCAEC19010PRAT

  Durada: 01/12/2019 - 30/11/2024

• Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Merck Farma y Química, S.L

  Codi: 19-IO-011

  Durada: 01/07/2019 - 30/06/2021

• Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer  

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Instituto de Salud Carlos III

  Codi: INT_BCN_Catalyst_18

  Durada: 01/03/2019 - 28/02/2023

• Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS).

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Fundación Quirón Salud

  Codi: FQuironSalud_Mama18

  Durada: 11/02/2019 - 10/02/2022